Pathological gamma oscillations, impaired dopamine release, synapse loss and reduced dynamic range of unitary glutamatergic synaptic transmission in the striatum of hypokinetic Q175 Huntington mice

Huntington's disease (HD) is a severe genetically inherited neurodegenerative disorder. Patients present with three principal phenotypes of motor symptoms: choreatic, hypokinetic-rigid and mixed. The Q175 mouse model of disease offers an opportunity to investigate the cellular basis of the hypokinetic-rigid form of HD. At the age of 1 year homozygote Q175 mice exhibited the following signs of hypokinesia: Reduced frequency of spontaneous movements on a precision balance at daytime (-55%), increased total time spent without movement in an open field (+42%), failures in the execution of unconditioned avoidance reactions (+32%), reduced ability for conditioned avoidance (-96%) and increased reaction times (+65%) in a shuttle box. Local field potential recordings revealed low-frequency gamma oscillations in the striatum as a characteristic feature of HD mice at rest. There was no significant loss of DARPP-32 immunolabeled striatal projection neurons (SPNs) although the level of DARPP-32 immunoreactivity was lower in HD. As a potential cause of hypokinesia, HD mice revealed a strong reduction in striatal KCl-induced dopamine release, accompanied by a decrease in the number of tyrosine hydroxylase-(TH)- and VMAT2-positive synaptic varicosities. The presynaptic TH fluorescence level was also reduced. Patch-clamp experiments were performed in slices from 1-year-old mice to record unitary EPSCs (uEPSCs) of presumed cortical origin in the absence of G-protein-mediated modulation. In HD mice, the maximal amplitudes of uEPSCs amounted to 69% of the WT level which matches the loss of VGluT1+/SYP+ synaptic terminals in immunostained sections. These results identify impairment of cortico-striatal synaptic transmission and dopamine release as a potential basis of hypokinesia in HD.

[1]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[2]  D. Sibley,et al.  Striatal neurochemical changes in transgenic models of Huntington's disease , 2002, Journal of neuroscience research.

[3]  P. Brown Oscillatory nature of human basal ganglia activity: Relationship to the pathophysiology of Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[4]  Jane S. Paulsen,et al.  Huntington disease: natural history, biomarkers and prospects for therapeutics , 2014, Nature Reviews Neurology.

[5]  A. Reiner,et al.  Immunohistochemical localization of DARPP-32 in striatal projection neurons and striatal interneurons: implications for the localization of D1-like dopamine receptors on different types of striatal neurons , 1991, Brain Research.

[6]  Xin Jin,et al.  Frontiers in Integrative Neuroscience Integrative Neuroscience , 2022 .

[7]  Ann M. Graybiel,et al.  Effects of Dopamine Depletion on Lfp Oscillations in Striatum Are Task-and Learning-dependent and Selectively Reversed by L-dopa Accessed Terms of Use Detailed Terms , 2022 .

[8]  B. Walmsley,et al.  Amplitude fluctuations in synaptic potentials evoked in cat spinal motoneurones at identified group Ia synapses. , 1983, The Journal of physiology.

[9]  E. Abercrombie,et al.  In vivo Dopamine Efflux is Decreased in Striatum of both Fragment (R6/2) and Full-Length (YAC128) Transgenic Mouse Models of Huntington's Disease , 2011, Front. Syst. Neurosci..

[10]  D. Faber,et al.  Tonic mGluR5/CB1‐dependent suppression of inhibition as a pathophysiological hallmark in the striatum of mice carrying a mutant form of huntingtin , 2013, The Journal of physiology.

[11]  A. I. Shapovalov,et al.  Relation between structural and release parameters at the frog sensory‐motor synapse. , 1984, The Journal of physiology.

[12]  Carlos Cepeda,et al.  Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease , 2003, The Journal of Neuroscience.

[13]  Mei Kwan,et al.  Comprehensive Behavioral and Molecular Characterization of a New Knock-In Mouse Model of Huntington’s Disease: zQ175 , 2012, PloS one.

[14]  R. Palmiter,et al.  Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice , 2014, Neurobiology of Disease.

[15]  M. Dragunow,et al.  The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease , 2000, Neuroscience.

[16]  J. Bradshaw,et al.  Electrophysiological measures as potential biomarkers in Huntington's disease: Review and future directions , 2010, Brain Research Reviews.

[17]  C. Cepeda,et al.  Dopamine and Glutamate in Huntington's Disease: A Balancing Act , 2010, CNS neuroscience & therapeutics.

[18]  T. Kita,et al.  Passive electrical membrane properties of rat neostriatal neurons in an in vitro slice preparation , 1984, Brain Research.

[19]  D. Housman,et al.  Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice , 2012, Proceedings of the National Academy of Sciences.

[20]  J. Penney,et al.  Differential loss of striatal projection systems in Huntington’s disease: a quantitative immunohistochemical study , 2004, Journal of Chemical Neuroanatomy.

[21]  Nicola Pavese,et al.  Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. , 2003, Brain : a journal of neurology.

[22]  P. Greengard,et al.  Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Brundin,et al.  Evidence for Dysfunction of the Nigrostriatal Pathway in the R6/1 Line of Transgenic Huntington's Disease Mice , 2002, Neurobiology of Disease.

[24]  H. Scheich,et al.  Learning a new behavioral strategy in the shuttle-box increases prefrontal dopamine , 2004, Neuroscience.

[25]  Vishwanath T. Anekonda,et al.  Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease. , 2012, Human molecular genetics.

[26]  R. Albin,et al.  Decreased striatal monoaminergic terminals in Huntington disease , 2000, Neurology.

[27]  George V. Rebec,et al.  Dysfunctional Behavioral Modulation of Corticostriatal Communication in the R6/2 Mouse Model of Huntington’s Disease , 2012, PloS one.

[28]  H. Steinbusch,et al.  Hyperdopaminergic Status in Experimental Huntington Disease , 2010, Journal of neuropathology and experimental neurology.

[29]  Jack R Glaser,et al.  Characterization of Neurophysiological and Behavioral Changes, MRI Brain Volumetry and 1H MRS in zQ175 Knock-In Mouse Model of Huntington's Disease , 2012, PloS one.

[30]  C. Colwell,et al.  The Q175 Mouse Model of Huntington’s Disease Shows Gene Dosage- and Age-Related Decline in Circadian Rhythms of Activity and Sleep , 2013, PloS one.

[31]  Carlos Cepeda,et al.  The corticostriatal pathway in Huntington's disease , 2007, Progress in Neurobiology.

[32]  M. Schäfer,et al.  Three Types of Tyrosine Hydroxylase-Positive CNS Neurons Distinguished by Dopa Decarboxylase and VMAT2 Co-Expression , 2006, Cellular and Molecular Neurobiology.

[33]  Joshua L. Plotkin,et al.  Impaired TrkB Receptor Signaling Underlies Corticostriatal Dysfunction in Huntington’s Disease , 2014, Neuron.

[34]  George V. Rebec,et al.  Dysregulated Neuronal Activity Patterns Implicate Corticostriatal Circuit Dysfunction in Multiple Rodent Models of Huntington's Disease , 2011, Front. Syst. Neurosci..

[35]  G. Sedvall,et al.  PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. , 1997, Brain : a journal of neurology.

[36]  M. Delong,et al.  Milestones in research on the pathophysiology of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[37]  A. Reiner,et al.  Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice , 2013, Neurobiology of Disease.

[38]  Gregor Thut,et al.  Prediction of response speed by anticipatory high‐frequency (gamma band) oscillations in the human brain , 2005, Human brain mapping.

[39]  Talia N. Lerner,et al.  RGS4 Is Required for Dopaminergic Control of Striatal LTD and Susceptibility to Parkinsonian Motor Deficits , 2012, Neuron.

[40]  Markus Siegel,et al.  Corticostriatal Coordination through Coherent Phase-Amplitude Coupling , 2014, The Journal of Neuroscience.

[41]  C. Cepeda,et al.  Rescuing the Corticostriatal Synaptic Disconnection in the R6/2 Mouse Model of Huntington’s Disease: Exercise, Adenosine Receptors and Ampakines , 2010, PLoS currents.

[42]  Martin Parent,et al.  The role of dopamine in Huntington's disease. , 2014, Progress in brain research.

[43]  Paul Greengard,et al.  Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors , 2010, Proceedings of the National Academy of Sciences.

[44]  J. Penney,et al.  Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis , 1995, Neuroscience.

[45]  R. Adalbert,et al.  Age-related axonal swellings precede other neuropathological hallmarks in a knock-in mouse model of Huntington's disease , 2014, Neurobiology of Aging.

[46]  Joshua L. Plotkin,et al.  Synaptically driven state transitions in distal dendrites of striatal spiny neurons , 2011, Nature Neuroscience.

[47]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[48]  C. Henneberger,et al.  Brain-derived neurotrophic factor modulates GABAergic synaptic transmission by enhancing presynaptic glutamic acid decarboxylase 65 levels, promoting asynchronous release and reducing the number of activated postsynaptic receptors , 2005, Neuroscience.

[49]  H. Yin,et al.  Huntingtin Is Required for Normal Excitatory Synapse Development in Cortical and Striatal Circuits , 2014, The Journal of Neuroscience.

[50]  F. Pierelli,et al.  Abnormal spinal cord pain processing in Huntington’s disease. The role of the diffuse noxious inhibitory control , 2011, Clinical Neurophysiology.

[51]  J. Brandt,et al.  Predictors of neuropathological severity in 100 patients with Huntington's disease , 2003, Annals of neurology.

[52]  A. Dvorzhak,et al.  High Frequency Stimulation of the Subthalamic Nucleus Leads to Presynaptic GABA(B)-Dependent Depression of Subthalamo-Nigral Afferents , 2013, PloS one.

[53]  A. Reiner,et al.  Differential loss of thalamostriatal and corticostriatal input to striatal projection neuron types prior to overt motor symptoms in the Q140 knock-in mouse model of Huntington's disease , 2014, Front. Syst. Neurosci..

[54]  R. Wightman,et al.  Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease , 2006, Journal of neurochemistry.

[55]  Weixing Shen,et al.  Dopaminergic modulation of striatal networks in health and Parkinson's disease , 2014, Current Opinion in Neurobiology.

[56]  S. Kirischuk,et al.  N‐ethylmaleimide increases release probability at GABAergic synapses in layer I of the mouse visual cortex , 2006, The European journal of neuroscience.

[57]  Carlos Cepeda,et al.  Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease. , 2015, Journal of neurophysiology.

[58]  C. Wilson,et al.  Potassium currents responsible for inward and outward rectification in rat neostriatal spiny projection neurons , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[59]  Vladimir Litvak,et al.  Beta Reactivity, Prospective Facilitation of Executive Processing, and Its Dependence on Dopaminergic Therapy in Parkinson's Disease , 2012, The Journal of Neuroscience.

[60]  Carlos Cepeda,et al.  Age-Dependent Alterations of Corticostriatal Activity in the YAC128 Mouse Model of Huntington Disease , 2009, The Journal of Neuroscience.

[61]  A. Parent,et al.  Serotonin and dopamine striatal innervation in Parkinson's disease and Huntington's chorea. , 2011, Parkinsonism & related disorders.

[62]  K. Murphy,et al.  Dysfunctional Dopaminergic Neurones in Mouse Models of Huntington's Disease: A Role for SK3 Channels , 2015, Neurodegenerative Diseases.

[63]  Charles J. Wilson,et al.  Feedforward and feedback inhibition in neostriatal GABAergic spiny neurons , 2008, Brain Research Reviews.

[64]  Bernardo L Sabatini,et al.  Phosphorylation of Ser1166 on GluN2B by PKA Is Critical to Synaptic NMDA Receptor Function and Ca2+ Signaling in Spines , 2014, The Journal of Neuroscience.

[65]  Joshua L. Plotkin,et al.  Corticostriatal synaptic adaptations in Huntington’s disease , 2015, Current Opinion in Neurobiology.

[66]  G. Rebec,et al.  Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes. , 2012, Basal ganglia.

[67]  G. Turrigiano The Self-Tuning Neuron: Synaptic Scaling of Excitatory Synapses , 2008, Cell.

[68]  S. W. Davies,et al.  Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[69]  J. Penney,et al.  Differential loss of striatal projection neurons in Huntington disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[70]  D. Surmeier,et al.  Neurochemical characterization of the striatum and the nucleus accumbens in L-type Cav1.3 channels knockout mice , 2012, Neurochemistry International.

[71]  D. James Surmeier,et al.  Corticostriatal and Thalamostriatal Synapses Have Distinctive Properties , 2008, The Journal of Neuroscience.

[72]  A. Reiner,et al.  Striatal parvalbuminergic neurons are lost in Huntington's disease: implications for dystonia , 2013, Movement disorders : official journal of the Movement Disorder Society.

[73]  F. Walker Huntington's disease , 2007, The Lancet.